DOV 102677 is a psychoactive drug being developed by Merck as an antidepressant and is currently in clinical trials. It is a so-called triple (re)uptake inhibitor (TUI) or serotonin-norepinephrine-dopamine reuptake inhibitor (SNDRI).
This page contains content from the copyrighted Wikipedia article "DOV-102677"; that content is used under the GNU Free Documentation License (GFDL). You may redistribute it, verbatim or modified, providing that you comply with the terms of the GFDL.
